mutation,domain,residue_position,frequency_percent,cancer_types,affects_epitope,resistance_mechanism,adc_impact,clinical_significance
S310F,Domain II,310,0.8,"Breast, Gastric, Bladder",Pertuzumab (reduced),"Reduced pertuzumab binding, altered dimerization",Minimal (does not affect T-DM1/T-DXd),May reduce pertuzumab efficacy
L755S,Kinase domain,755,2.1,"Breast, NSCLC",No (intracellular),"Lapatinib/neratinib resistance, HER2 activation",None (ADC binding unaffected),"TKI resistance, ADC remains effective"
V777L,Kinase domain,777,1.5,"Breast, Colorectal",No (intracellular),Increased kinase activity,None (ADC binding unaffected),"Activating mutation, ADC effective"
T798M,Kinase domain,798,0.5,Breast (acquired),No (intracellular),"Gatekeeper mutation, TKI resistance",None (ADC binding unaffected),"TKI resistance, ADC alternative"
D769H/Y,Kinase domain,769,1.2,"Breast, NSCLC",No (intracellular),Altered kinase activity,None (ADC binding unaffected),May affect TKI sensitivity
R678Q,Juxtamembrane,678,0.3,Breast,Potentially (near Domain IV),Unknown mechanism,Under investigation,"Rare, significance unclear"
HER2 loss/downregulation,N/A,N/A,15.0,All HER2+ cancers (post-treatment),Complete loss,"Reduced target expression, antigen escape",Major - loss of target,Major resistance mechanism
p95-HER2 (truncated),N-terminal truncation,611-start,20.0,Breast (aggressive),Loss of ECD (Domains I-IV),"Loss of extracellular domain, no mAb binding",Major - no binding site,"Trastuzumab resistant, poor prognosis"
HER2 splice variants,Various,N/A,5.0,Breast,Variable,Altered protein structure,Variable - epitope dependent,May affect therapy response
